Monte Rosa Therapeutics

Monte Rosa Therapeutics

Biotechnology, 645 Summer St Ste 102, Boston, Massachusetts, 02210, United States, 51-200 Employees

monterosatx.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is MONTE ROSA THERAPEUTICS

Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pio...

Read More

map
  • 645 Summer St Ste 102, Boston, Massachusetts, 02210, United States Headquarters: 645 Summer St Ste 102, Boston, Massachusetts, 02210, United States
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 1731

checked-icon Does something look wrong? Fix it. | View contact records from MONTE ROSA THERAPEUTICS

Monte Rosa Therapeutics Org Chart and Mapping

Employees

Chris King

VP of Nonclinical Development & Clinical Pharmacology

Mackenzie Barber

Senior Research Associate I, Biochemistry

Filip Janku

Chief Medical Officer

Sue Kim

Associate Director, Operations

Philip Nickson

SVP and General Counsel

Jennifer Champoux

Chief People and Operations Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Monte Rosa Therapeutics

Answer: Monte Rosa Therapeutics's headquarters are located at 645 Summer St Ste 102, Boston, Massachusetts, 02210, United States

Answer: Monte Rosa Therapeutics's phone number is 61********

Answer: Monte Rosa Therapeutics's official website is https://monterosatx.com

Answer: Monte Rosa Therapeutics's revenue is $10 Million to $25 Million

Answer: Monte Rosa Therapeutics's SIC: 1731

Answer: Monte Rosa Therapeutics has 51-200 employees

Answer: Monte Rosa Therapeutics is in Biotechnology

Answer: Monte Rosa Therapeutics contact info: Phone number: 61******** Website: https://monterosatx.com

Answer: Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access